glp-1 drugs covered by medicare & in 2026: What You MUST Know Fmr. FDA Commissioner weighs in

A long-acting glucose-dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon-like peptide-1 receptor agonist therapy

February 2024: In February 2024, the United States Judicial Panel on Multidistrict Litigation (MDL Panel), agreed to consolidate lawsuits involving glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including Trulicity

Generic versions became available in 2022, reducing costs to $150-250 monthly depending on the pharmacy and dosage strength

Author contributions QL: Conceptualization, Data curation, Formal analysis, Writing original draft, Writing review & editing

The team identified elenolic acid -- a compound derived from oleuropein, which is abundant in olive fruit and EVOO -- as a direct stimulator of GLP-1 and PYY (peptide YY, another satiety hormone) release from gut L-cells

Table S8